528 related articles for article (PubMed ID: 25755422)
1. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease.
Mishra A; Younossi ZM
J Clin Exp Hepatol; 2012 Jun; 2(2):135-44. PubMed ID: 25755422
[TBL] [Abstract][Full Text] [Related]
2. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
Vernon G; Baranova A; Younossi ZM
Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
4. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
5. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
6. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges.
Hashimoto E; Tokushige K; Ludwig J
Hepatol Res; 2015 Jan; 45(1):20-8. PubMed ID: 24661406
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic Fatty Liver Disease in South Asians: A Review of the Literature.
Singh S; Kuftinec GN; Sarkar S
J Clin Transl Hepatol; 2017 Mar; 5(1):76-81. PubMed ID: 28507930
[TBL] [Abstract][Full Text] [Related]
9. The epidemiology of non-alcoholic fatty liver disease.
Bellentani S
Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review.
Eguchi Y; Wong G; Lee EI; Akhtar O; Lopes R; Sumida Y
JGH Open; 2020 Oct; 4(5):808-817. PubMed ID: 33102749
[TBL] [Abstract][Full Text] [Related]
11. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
13. The Natural Course of Non-Alcoholic Fatty Liver Disease.
Calzadilla Bertot L; Adams LA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
[TBL] [Abstract][Full Text] [Related]
14. Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective.
Samji NS; Verma R; Satapathy SK
J Clin Exp Hepatol; 2019; 9(4):497-505. PubMed ID: 31516266
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of non-alcoholic fatty liver disease: Polish-case control study.
Kempiński R; Łukawska A; Krzyżanowski F; Ślósarz D; Poniewierka E
Adv Clin Exp Med; 2019 Dec; 28(12):1615-1620. PubMed ID: 31025557
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.
Duseja A; Singh SP; Saraswat VA; Acharya SK; Chawla YK; Chowdhury S; Dhiman RK; Jayakumar RV; Madan K; Misra SP; Mishra H; Modi SK; Muruganathan A; Saboo B; Sahay R; Upadhyay R
J Clin Exp Hepatol; 2015 Mar; 5(1):51-68. PubMed ID: 25941433
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
18. NASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed?
Canbay A; Sowa JP; Syn WK; Treckmann J
Visc Med; 2016 Aug; 32(4):234-238. PubMed ID: 27722159
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and diagnosis of NAFLD/NASH.
Hashimoto E; Taniai M; Tokushige K
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease and cardiovascular disease.
Hyogo H; Chayama K; Yamagishi S
Curr Pharm Des; 2014; 20(14):2403-11. PubMed ID: 23844815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]